Drug Trial Radar · NCT05352815
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec
Last checked: Nov 20, 2026Latest source record: Dec 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,291
Actual
Start
Jun 1, 2022
Primary completion
Mar 19, 2024
Study completion Apr 23, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes. The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec. Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe. Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach. The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.
Conditions
- Diabetes Mellitus, Type 2
Interventions
IcoSemaDrug
Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Insulin icodecDrug
Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Haemoglobin (HbA1c)Time frame: Baseline (Week 0), Week 52
Locations
281 sites in 22 countries. Site status is shown where the registry gives one.
Pri Med Grp dba/Gil Ctr Fam
Gilbert, Arizona
Lenzmeier Fam Med CCT Research
Glendale, Arizona
Phoenician Centers for Research & Innovation PCRI
Phoenix, Arizona
Medical Investigations, Inc.
Little Rock, Arkansas
John Muir Physicians Network
Concord, California
Headlands Research California, LLC
Escondido, California
Scripps Whittier Diabetes Inst
La Jolla, California
Clinical Trials Research_Sacramento
Lincoln, California
Torrance Clin Res Inst, Inc.
Lomita, California
Pacific Clinical Studies
Los Alamitos, California
Downtown LA Res Ctr. Inc.
Los Angeles, California
Velocity Clin Res Los Angeles
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Clinical Trials Research_Sacramento_0
Sacramento, California
San Diego Family Care
San Diego, California
NorCal Endocrinology and Internal Medicine
San Ramon, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Creekside Endocrine Associates, PC
Denver, Colorado
Clinical Res Of W Florida Inc
Clearwater, Florida
Northeast Research Institute
Fleming Island, Florida
University of Miami
Miami, Florida
Adult Medicine of Lake County, Inc.
Mt. Dora, Florida
Suncoast Clin Res Port Richey
New Port Richey, Florida
Clinical Neuroscience Solution
Orlando, Florida
Florida Inst For Clin Res
Orlando, Florida
Metabolic Research Institute Inc
West Palm Beach, Florida
Javara/Privia Med Grp GA,LLC
Albany, Georgia
Emory University SOM
Atlanta, Georgia
Javara Inc.
Fayetteville, Georgia
Physicians Research Assoc. LLC
Lawrenceville, Georgia
Endocrine Research Solutions
Roswell, Georgia
East West Med Res Inst
Honolulu, Hawaii
Saltzer Medical Group Research
Nampa, Idaho
UnityPoint Health-Diabetes Care Center
Peoria, Illinois
Endeavor Health
Skokie, Illinois
Iowa Diab & Endo Res Center
West Des Moines, Iowa
Cotton O'Neil Diab & Endo Ctr
Topeka, Kansas
The Research Group of Lexington LLC
Lexington, Kentucky
Barnum Medical Research Inc.
Natchitoches, Louisiana
New Orleans Center for Clinical Research
New Orleans, Louisiana
Showing 40 of 281 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.